As India struggles with vaccine shortages and a laggard inoculation programme, a clutch of local manufacturers, including Hetero Group of Companies, Gland Pharma and Stelis Biopharma has set out to produce the contentious Sputnik V vaccine in a bid to alleviate supply constraints. Subscribe to Forbes India for early access
Interior View of Hetero Biopharma manufacturing facility, Jadcherla, Hyderabad, India.
(This story appears in the 04 June, 2021 issue of Forbes India. To visit our Archives, click here.)